Evidence map›Paper›PMID 41021104›Full record

ArticleDiscover oncology2025

Multi-omics analysis of ILF2 reveals its prognostic value and functional roles across pan-cancer.

Huan Xiong, Zewei Chen, Junjie Xu, Hailin Tang, Xiaoyan Li, Anli Yang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Huan Xiong *Department of Medical Records, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510080, Guangdong, China.
Zewei Chen *Department of Oncology, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, 510060, Guangdong, China.
Junjie Xu *Department of Oncology, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, 510060, Guangdong, China.
Hailin TangDepartment of Oncology, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, 510060, Guangdong, China. tanghl@sysucc.org.cn.
Xiaoyan LiDepartment of Oncology, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, 510060, Guangdong, China. lixiaoy@sysucc.org.cn.
Anli YangDepartment of Oncology, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, 510060, Guangdong, China. yangal@sysucc.org.cn.

Funding

Guangzhou Municipal Science and Technology Project 2024A04J9904the National Natural Science Foundation of China 82203127
6 · The paper itself

Abstract

backgroundThe growing incidence and high mortality of malignant tumors render them a persistent challenge to global health. Interleukin enhancer-binding factor 2 (ILF2), a nuclear protein involved in gene regulation, has been found to be aberrantly expressed in various cancers; however, its pan-cancer roles remain unclear.

methodsThis study presents an extensive pan-cancer analysis We systematically evaluated the expression patterns, prognostic and diagnostic significance, genetic alterations, alternative splicing events, functional pathways, immune infiltration characteristics, and therapeutic responses of ILF2 across diverse cancer types.

resultsILF2 was broadly upregulated across multiple cancers and correlated with poor prognosis, genomic alterations, and proliferation-related pathways. Its expression was also associated with immune infiltration and immune subtypes. In hepatocellular carcinoma, ILF2 mainly expresses in malignant hepatocytes at the single-cell RNA-seq level, and high ILF2 predicted therapeutic resistance and worse survival outcomes.

conclusionILF2 may serve as a potential biomarker for cancer diagnosis, prognosis, and therapeutic targeting. In particular, it holds promise as a novel therapeutic target in hepatocellular carcinoma.

Indexed as

BiomarkerILF2Multi-omicsPan-cancerPrognosis

Identifiers

PMID41021104
PMCPMC12480141

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.